Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Herchenhorn

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2011
Targeting epidermal growth factor receptor to optimize chemoradiotherapy in locally advanced head and neck cancer: has biology been taken into account?Daniel Herchenhorn, Carlos G Ferreira
Revista Do Hospital Das Clinicas|March 19, 2004
Advances in radiochemotherapy in the treatment of head and neck cancerDaniel Herchenhorn, Fernando Luiz Dias
Clinics (Sao Paulo, Brazil)|April 24, 2012
Castration-resistant prostate cancer: systemic therapy in 2012Fernando C Maluf, Oren Smaletz, Daniel Herchenhorn
Critical Reviews in Oncology/Hematology|March 17, 2021
Sequential therapies for advanced urothelial cancer: Hope meets new challengesDaniel Herchenhorn, Vinicius Freire, Thamires Oliveira, et al.
Anti-Cancer Drugs|September 23, 2003
Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabineGuilherme Rabinowits, Daniel Herchenhorn, Milton Rabinowits, et al.
Frontiers in Immunology|December 4, 2025
Safety and effectiveness of immune checkpoint inhibitors in patients with preexisting autoimmune diseases: a systematic reviewYasmim Dias, Viviane Silva, Maria Fernanda de Carvalho, et al.
Radiation Oncology (London, England)|March 8, 2022
Photobiomodulation as a treatment for dermatitis caused by chemoradiotherapy for squamous cell anal carcinoma: case report and literature reviewFabiana Hottz, Daniel Herchenhorn, Juliana Lenzi, et al.
Clinical Advances in Hematology & Oncology : H&O|August 2, 2023
New drug approvals in prostate cancer and their effect on the treatment landscapeChinmay Jani, Nour Abdallah, Pavlina Chrysafi, et al.
Oncotargets and Therapy|October 8, 2016
Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinomaCarlos H Barrios, Daniel Herchenhorn, Matías Chacón, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology|August 27, 2016
Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experienceRafael Corrêa Coelho, Tomás Reinert, Franz Campos, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2011
Targeting epidermal growth factor receptor to optimize chemoradiotherapy in locally advanced head and neck cancer: has biology been taken into account?Daniel Herchenhorn, Carlos G Ferreira
Revista Do Hospital Das Clinicas|March 19, 2004
Advances in radiochemotherapy in the treatment of head and neck cancerDaniel Herchenhorn, Fernando Luiz Dias
Clinics (Sao Paulo, Brazil)|April 24, 2012
Castration-resistant prostate cancer: systemic therapy in 2012Fernando C Maluf, Oren Smaletz, Daniel Herchenhorn
Critical Reviews in Oncology/Hematology|March 17, 2021
Sequential therapies for advanced urothelial cancer: Hope meets new challengesDaniel Herchenhorn, Vinicius Freire, Thamires Oliveira, et al.
Anti-Cancer Drugs|September 23, 2003
Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabineGuilherme Rabinowits, Daniel Herchenhorn, Milton Rabinowits, et al.
Frontiers in Immunology|December 4, 2025
Safety and effectiveness of immune checkpoint inhibitors in patients with preexisting autoimmune diseases: a systematic reviewYasmim Dias, Viviane Silva, Maria Fernanda de Carvalho, et al.
Radiation Oncology (London, England)|March 8, 2022
Photobiomodulation as a treatment for dermatitis caused by chemoradiotherapy for squamous cell anal carcinoma: case report and literature reviewFabiana Hottz, Daniel Herchenhorn, Juliana Lenzi, et al.
Clinical Advances in Hematology & Oncology : H&O|August 2, 2023
New drug approvals in prostate cancer and their effect on the treatment landscapeChinmay Jani, Nour Abdallah, Pavlina Chrysafi, et al.
Oncotargets and Therapy|October 8, 2016
Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinomaCarlos H Barrios, Daniel Herchenhorn, Matías Chacón, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology|August 27, 2016
Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experienceRafael Corrêa Coelho, Tomás Reinert, Franz Campos, et al.
Pageof 6